Psychodermatology 2.0. towards improved assessment and effective internet-based interventions

Contains fulltext : 169320.pdf (publisher's version ) (Open Access)Radboud University, 10 mei 2017Promotores : Evers, A.W.M., Kerkhof, P.C.M. van de Co-promotor : Middendorp, H. va

How stress affects the skin: from designs to mechanisms

Health and self-regulatio

Psychological treatments for dermatological conditions

FSW - Self-regulation models for health behavior and psychopathology - ou

eHealth cognitieve gedragstherapie voor patiënten met chronische somatische aandoeningen

-based cognitive behavioral therapy for patients with chronic somatic conditions Many patients with chronic somatic conditions regularly experience impairments in physical and psychological functioning in their daily life. A way to support these patients is to offer online programs based on cognitive behavioral therapy (Internet-based cognitive behavioral therapy; ICBT). Although a substantial evidence base already exists regarding the effectiveness of ICBT in treating, for example, depressive symptoms, research on ICBT for chronic somatic conditions is still upcoming. In recent years, a growing number of randomized controlled trials were published that examined the effectiveness of ICBT in various chronic somatic conditions. To systematically and quantitatively evaluate the results of these studies, a metaanalysis was conducted, the results of which are discussed in this article. Results indicated that ICBT is also overall effective for chronic somatic conditions, with small to moderate effect sizes. Larger effects were occasionally found for disease-specific outcomes such as disease symptoms and disease-specific quality of life. A longer treatment duration was found to be marginally related to a larger decrease in depressive symptoms. In addition to the results of the meta-analysis, this article provides an overview of the recent literature regarding several clinically relevant ICBT topics: cost-effectiveness, guided ICBT interventions versus self-help, the role of treatment duration, and optimal design and implementation of eHealth interventions.FSW - Self-regulation models for health behavior and psychopathology - ou

Itch-related avoidance and attentional biases in patients with psoriasis?

Health and self-regulatio

Quality of life in cutaneous T-cell lymphoma patients receiving mogamulizumab: important factors to consider

Background: Erythrodermic cutaneous T-cell lymphoma (E-CTCL) is associated with a poor prognosis and severe symptoms. Objective: To establish insights into the quality of life (QoL), expectations, and treatment satisfaction of E-CTCL patients receiving mogamulizumab. Methods: Outcomes of this prospective cohort study conducted between September 2020 and August 2021 at the Leiden University Medical Center included the dermatology-specific QoL (Skindex-29), health-related QoL (RAND-12), degree of itch, pain, and fatigue (Visual Analogue Scale), patient’s expectations, and treatment satisfaction (Client Satisfaction Questionnaire-8 (CSQ-8)), measured at baseline and after six months. Results: 13 patients with E-CTCL were included. Most patients anticipated a positive treatment effect on symptoms. Five patients (46%) improved one or more clinical categories regarding the symptoms domain, six (55%) regarding emotions, four (36%) regarding functioning, and four (36%) regarding the overall Skindex-29 score compared to baseline. The Mental Component Score clinically improved from 31 (IQR 29–51) at baseline to 38 (IQR 25–51). The median VAS itch improved significantly from baseline (8 (IQR 7–10) vs. 3 (IQR 1–8), p = 0.024). Most patients (n = 7) were “very satisfied” with their treatment. Limitations: There was a limited number of patients due to the rarity of the disease. Conclusion: In general, mogamulizumab has a favorable effect on biochemical- and dermatology-specific QoL and physical functioning in some patients, with high treatment satisfaction. Itch especially improved over time in most patients. The treatment satisfaction was generally high. Mogamulizumab seems to be an effective treatment that improves the QoL in patients with E-CTCL. Dermatology-oncolog

Patient-reported outcome measurements in facial skin surgery and a comparison between Mohs micrographic surgery and conventional excisions

Background: Knowledge of the psychosocial impact of facial skin surgery on  patients can help improve counselling strategies.Objectives: The  objective  was  to  measure  the  psychological  impact  of  facial  skin  cancer  surgery  on  patients  over  a  1-year  period.  Secondary  objective  was  to  meas-ure  the  difference  between  Mohs  micrographic  surgery  (MMS)  and  conventional  excision (CE) on these parameters.Methods: This observational survey study was conducted between March 2019 and July 2020. Patients who had facial skin surgery using MMS or CE were selected. Five surveys  were  conducted  on  four  timepoints  (preoperative,  1  week,  3  months  and  1   year  post-operative)  measuring  the  quality  of  life,  perceived  stigmatization,  body  image, satisfaction with facial appearance and psychosocial distress.Results: A total of 228 patients (MMS 154 patients, CE 74 patients) were included for the analysis. Scores for quality of life did not significantly change, in the year after surgery (PCS-12 mean 50.5, SD 9.3 and MCS-12 50.6, SD 9.4); however, stigmatiza-tion (F (3, 235,39) 7,26, p </p

Implicit stigmatization-related biases in individuals with skin conditions and their significant others

FSW - Self-regulation models for health behavior and psychopathology - ou